Healthcare provider profile · identity verified

Crisanto Gualberto, M.D.

General Practice · VANDALIA, MO · NPI 1043285398

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	346	42
Metoprolol Tartrate	Metoprolol Tartrate	343	51
Levothyroxine Sodium	Levothyroxine Sodium	313	35
Metformin Hcl	Metformin Hcl	285	46
Donepezil Hcl	Donepezil Hcl	252	18
Furosemide	Furosemide	249	27
Lisinopril	Lisinopril	217	23
Potassium Chloride	Potassium Chloride	208	26
Amlodipine Besylate	Amlodipine Besylate	199	43
Eliquis	Apixaban	192	19
Omeprazole	Omeprazole	173	18
Escitalopram Oxalate	Escitalopram Oxalate	152	14
Metoprolol Succinate	Metoprolol Succinate	152	15
Pantoprazole Sodium	Pantoprazole Sodium	137	24
Lorazepam	Lorazepam	128	12
Losartan Potassium	Losartan Potassium	127	12
Tramadol Hcl	Tramadol Hcl	120	20
Azithromycin	Azithromycin	116	85
Gabapentin	Gabapentin	109	17
Allopurinol	Allopurinol	103	17
Divalproex Sodium	Divalproex Sodium	101	suppressed
Glipizide	Glipizide	100	17
Simvastatin	Simvastatin	89	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	88	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	87	16
Carvedilol	Carvedilol	86	suppressed
Clopidogrel	Clopidogrel Bisulfate	72	13
Spironolactone	Spironolactone	72	suppressed
Meloxicam	Meloxicam	71	11
Memantine Hcl	Memantine Hcl	71	suppressed
Pravastatin Sodium	Pravastatin Sodium	71	22
Tizanidine Hcl	Tizanidine Hcl	71	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	66	suppressed
Mirtazapine	Mirtazapine	66	suppressed
Montelukast Sodium	Montelukast Sodium	66	12
Sertraline Hcl	Sertraline Hcl	63	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	61	23
Esomeprazole Magnesium	Esomeprazole Magnesium	61	suppressed
Hydrocortisone	Hydrocortisone	60	suppressed
Prednisone	Prednisone	53	35
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	53	37
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	52	14
Enalapril Maleate	Enalapril Maleate	51	11
Clonidine Hcl	Clonidine Hcl	50	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	49	suppressed
Baclofen	Baclofen	47	suppressed
Indapamide	Indapamide	46	suppressed
Ropinirole Hcl	Ropinirole Hcl	45	suppressed
Celecoxib	Celecoxib	43	suppressed
Fluticasone Propionate	Fluticasone Propionate	41	22
Oxybutynin Chloride Er	Oxybutynin Chloride	41	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	39	23
Paroxetine Hcl	Paroxetine Hcl	38	suppressed
Trazodone Hcl	Trazodone Hcl	38	12
Carbidopa-Levodopa	Carbidopa/Levodopa	36	suppressed
Clindamycin Hcl	Clindamycin Hcl	34	22
Rosuvastatin Calcium	Rosuvastatin Calcium	34	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	suppressed
Bupropion Xl	Bupropion Hcl	32	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	32	suppressed
Memantine Hcl Er	Memantine Hcl	32	suppressed
Amoxicillin	Amoxicillin	31	24
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	31	suppressed
Bumetanide	Bumetanide	31	suppressed
Benztropine Mesylate	Benztropine Mesylate	30	suppressed
Lithium Carbonate	Lithium Carbonate	30	suppressed
Lovastatin	Lovastatin	30	suppressed
Topiramate	Topiramate	30	suppressed
Famotidine	Famotidine	29	suppressed
Amiodarone Hcl	Amiodarone Hcl	28	suppressed
Sucralfate	Sucralfate	28	suppressed
Bupropion Hcl Sr	Bupropion Hcl	27	suppressed
Latanoprost	Latanoprost	27	suppressed
Trandolapril	Trandolapril	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	17
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Cephalexin	Cephalexin	25	21
Atenolol	Atenolol	23	suppressed
Dexamethasone Sodium Phosphate	Dexamethasone Sodium Phosphate	23	18
Finasteride	Finasteride	23	suppressed
Jardiance	Empagliflozin	23	suppressed
Torsemide	Torsemide	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	14
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	21	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	21
Buspirone Hcl	Buspirone Hcl	20	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	19	19
Chlorthalidone	Chlorthalidone	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Digoxin	Digoxin	19	suppressed
Levetiracetam	Levetiracetam	19	suppressed
Benazepril Hcl	Benazepril Hcl	18	suppressed
Entresto	Sacubitril/Valsartan	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Valsartan	Valsartan	16	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	15	suppressed
Gemfibrozil	Gemfibrozil	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Folic Acid	Folic Acid	13	suppressed
Levofloxacin	Levofloxacin	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Alendronate Sodium	Alendronate Sodium	12	suppressed
Azathioprine	Azathioprine	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Prednisolone Acetate	Prednisolone Acetate	12	suppressed
Temazepam	Temazepam	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error